StockData
DexCom Inc logo

DexCom Inc (DXCM) KPIs and segments

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.52+0.48 (+0.59%)

Close on Nov 18, 2026Market cap $30.78BP/E 32.5Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của DexCom · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của DexCom: 61 chỉ số vận hành, trong đó có Global Active CGM Customer Base, Largest U.S. Private Third-Party Payors Covering CGM và Wholesale Distributor Channel Revenue, lấy từ 177 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
United States($M)
970933832892852841751803702732653769
International($M)
375375360368357316286311292272268265
Wholesale Distributor Channel Revenue($M)3
1,1481,1021,0101,0751,026978880948843860779898
U.S. Wholesale Distributor Revenue($M)
933894797857818800721773
International Wholesale Distributor Revenue($M)
215209213218208178159175
Wholesale Distributor Share of Total Revenue (Legacy Table through Q3 2025)(%)
85.0%85.0%85.0%85.0%86.0%85.0%
Direct Channel Revenue (Direct-to-Patient & E-Commerce)($M)3
197206182184183179156166151144142136
U.S. Direct Channel Revenue (Includes Stelo OTC Biosensor)($M)
36.739.935.434.533.84129.929.6
International Direct Channel Revenue($M)
160166146150150138126136
Direct Channel Share of Total Revenue (Legacy Table through Q3 2025)(%)
15.0%15.0%15.0%15.0%14.0%15.0%
Disposable Sensor & Other Revenue (Legacy Table through Q3 2025)($M)2
1,1751,1189971,069952947854947
Disposable Sensor & Other Share of Total Revenue (Legacy)(%)
97.0%97.0%96.0%96.0%96.0%94.0%93.0%92.0%
Disposable Sensor & Other Revenue YoY Growth (Legacy)(%)
23.0%18.0%17.0%13.0%9.0%22.0%31.0%32.0%
Reusable Hardware Revenue — Transmitters & Receivers (Legacy Table through Q3 2025)($M)2
34.239.338.84542.457.366.787.5
Reusable Hardware Share of Total Revenue (Legacy)(%)
3.0%3.0%4.0%4.0%4.0%6.0%7.0%8.0%
Reusable Hardware Revenue YoY Growth (Legacy)(%)
-19.0%-31.0%-42.0%-49.0%-58.0%-39.0%-26.0%-13.0%
Accrued Pharmacy Rebates (Ending Liability)($M)1
1,6151,6521,5471,4881,3731,3451,1561,1361,1601,1651,050951
Unbilled Contract Receivables($M)
19.919.916.916.916.61714.715.216.11410.18
Product Warranty Accrual (Ending Balance)($M)
17.45.609.2010.417.3185.905.805.907.2012.6
Worldwide Organic Revenue($M)5
1,3461,2981,1651,2501,1981,1511,0461,1089951,0059151,018
Worldwide Organic Revenue YoY Growth(%)
11.0%12.0%12.0%12.0%20.0%15.0%14.0%8.0%3.0%16.0%25.0%26.0%
Worldwide Reported Revenue YoY Growth(%)
11.0%13.0%15.0%13.0%22.0%15.0%12.0%8.0%2.0%15.0%24.0%27.0%
Worldwide Reported Revenue QoQ Growth(%)
3.0%10.0%-5.0%4.0%5.0%12.0%-7.0%12.0%-1.0%9.0%-11.0%6.0%
Foreign Exchange Impact Excluded from Organic Revenue($M)
1.70-9.90-26.6-9.40-11.4-6.209.90-5.300.500.80-3.20-8.20
Acquired Non-CGM Revenue Adjustment($M)
-0.70-0.200000000000
International Organic Revenue($M)7
376365333359346310296305293273262249
International Organic Revenue YoY Growth(%)
5.0%16.0%17.0%15.0%18.0%14.0%12.0%19.0%16.0%10.0%26.0%23.0%
International Reported Revenue YoY Growth(%)
5.0%19.0%26.0%18.0%22.0%16.0%7.0%17.0%12.0%7.0%24.0%27.0%
International Reported Revenue QoQ Growth(%)
0.0%4.0%-2.0%3.0%13.0%11.0%-8.0%6.0%7.0%2.0%1.0%2.0%
International Share of Total Reported Revenue(%)
28.0%29.0%30.0%29.0%30.0%27.0%28.0%28.0%29.0%27.0%29.0%26.0%
U.S. Reported Revenue YoY Growth(%)
14.0%11.0%11.0%11.0%21.0%15.0%15.0%4.0%-2.0%19.0%24.0%27.0%
U.S. Reported Revenue QoQ Growth(%)
4.0%12.0%-7.0%5.0%1.0%12.0%-7.0%14.0%-4.0%12.0%-15.0%8.0%
U.S. Share of Total Reported Revenue(%)
72.0%71.0%70.0%71.0%70.0%73.0%72.0%72.0%71.0%73.0%71.0%74.0%
Non-GAAP Gross Profit($M)1
875839757800741696596661626638569664
Non-GAAP Gross Margin(%)
65.1%64.1%63.5%63.5%61.3%60.1%57.5%59.4%63.0%63.5%61.8%64.2%
Non-GAAP Operating Income($M)4
340328264332273222143210212195140243
Non-GAAP Operating Margin(%)
25.3%25.1%22.2%26.3%22.6%19.2%13.8%18.8%21.3%19.5%15.2%23.5%
Operating Adjustment — Amortization of Acquired Intangibles($M)
11.99.4087.9087.907.9088.308.4010.410.1
Operating Adjustment — Business Transition & Related Items($M)
0.400.601.100.6022.71.101-0.90269.903.502
Operating Adjustment — Patent Infringement Litigation Costs($M)
0000-0.300.200.5013.525.722.325.213.7
Adjusted EBITDA($M)1
435421365422368328230300300284221322
Adjusted EBITDA Margin(%)
32.4%32.2%30.6%33.5%30.5%28.3%22.2%27.0%30.2%28.3%24.0%31.1%
Non-GAAP Net Income($M)2
275269216265243193128178180174128203
Non-GAAP Diluted EPS($)
0.730.700.560.680.610.480.320.450.450.430.320.50
Non-GAAP Diluted Weighted-Average Shares(M)
376382386391400401400399403409409407
Full-Year Revenue Guidance Issued in Quarter — Low Bound($M)3
5,2005,1805,1604,630
Full-Year Revenue Guidance Issued in Quarter — High Bound($M)
5,2505,2505,2504,650
Full-Year Revenue Growth Guidance — Low Bound(%)
12.0%11.0%11.0%15.0%
Full-Year Revenue Growth Guidance — High Bound(%)
13.0%13.0%13.0%15.0%
Segment Operating Expense — Payroll & Employee Benefits($M)8
241232224210233222220180190200
Segment Operating Expense — Marketing & Advertising($M)
96.490.885.685.475.778.870.465.786.461.5
Segment Operating Expense — IT Software & Data Processing($M)
43.74038.336.436.83635.133.231.332.1
Segment Operating Expense — Consulting & Professional Fees($M)
41.340.835.238.133.135.132.759.957.258
Segment Operating Expense — Operating Share-Based Compensation($M)
34.135.940.532.344.141.33139.840.635.3
Segment Operating Expense — Equipment, Office & Facilities($M)
30.827.127.325.422.822.521.520.320.922.2
Segment Operating Expense — Travel & Entertainment($M)
17.317.721.515.315.214.319.614.516.121
Segment Operating Expense — R&D Supplies & Clinical Trials($M)
14.812.910.815.817.714.413.718.21715.7
Segment Operating Expense — Other Segment Items($M)
0.802.20-0.3000.702.501.900.800.303.50
Total Allocated Share-Based Compensation Expense($M)3
36.83943.33545.145.334.243.343.444.73936.9
Share-Based Compensation — Cost of Sales($M)
2.703.102.802.70143.2033.604.103.703.50
Share-Based Compensation — Research & Development($M)
10.39.7011.610.712.213.512.813.713.113.911.511.2
Share-Based Compensation — Selling, General & Administrative($M)
23.826.228.921.631.927.818.226.626.726.723.822.2
Finished Goods Inventory($M)3
463387310267260131108187248257238210
Raw Materials & Components Inventory($M)
231233248258266346366327289249301320
Work in Process Inventory($M)
77.310713610578.69464.328.149.864.849.830
Excess, Obsolete & Quality-Control Inventory Write-Downs($M)
3345.638.639.8168.8028.223.30.109.30
Gross Property, Plant & Equipment($M)8
2,5142,5372,4662,4192,2812,2232,0902,0181,9561,7661,6581,623
Manufacturing Machinery & Equipment (Gross)($M)
1,1751,0291,0151,016999990955909884797735683
Buildings & Manufacturing Facilities (Gross)($M)
504389326320311310297291267248216191
Construction in Progress (Automated Production Lines & Athenry Plant)($M)
327614631594492446372355349285275328
Leasehold Improvements (Gross)($M)
299304302302297297293294291284284283
Computer Equipment & Software (Gross)($M)
98.998.991.687.885.982.979.976.676.871.267.565.8
Land & Land Improvements (Gross)($M)
66.557.858.358.356.556.653.453.150.545.143.234.5
Furniture & Fixtures (Gross)($M)
44.143.542.14140.340.640.240.238.337.136.936.9
Accumulated Depreciation & Amortization on PP&E($M)
970959906859810766725678637583549509
Operating Lease Liabilities — Noncurrent($M)2
77.582.66973.450.654.759.76571.176.875.880.1
Operating Lease Liabilities — Current($M)
20.720.720.521.623.623.422.622.522.321.620.721.1
Finance Lease Liabilities — Noncurrent($M)
5152.353.553.854.656.257.658.558.258.157.658.6
Total Global Workforce1
Current Employee-Related & Payroll Liabilities($M)
160136122169170129111112106116111171
DexCom FDA 510(k) Clearances1
131201000120
U.S. MedTech Industry Total FDA 510(k) Clearances
855923756806797886736856767793713877
DexCom FDA PMA & PMA Supplement Approvals1
000000000010
U.S. MedTech Industry Total FDA PMA Approvals
565608567525585588524683538550459656
DexCom FDA Medical Device Recall Events1
040155300000
DexCom FDA Recall Enforcement Reports
130155300000
DexCom FDA MAUDE Adverse Event Reports (Total MDRs)4
79,33761,665120,98177,641107,94892,46875,87789,10996,95480,39874,23074,471
DexCom MAUDE — Device Malfunction Reports
76,94059,798119,28275,736105,73590,79274,40487,91095,61879,07473,10473,550
DexCom MAUDE — Patient Injury Reports
2,2151,8521,6831,8912,1901,6701,4671,1881,3261,3161,122919
DexCom MAUDE — Death Reports
11151513112666841
U.S. MedTech Industry Total MAUDE Reports
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
U.S. Producer Price Index — Electromedical & Electrotherapeutic Apparatus5
92.8092.1092.0091.6090.7090.3090.1089.5089.3088.4088.3087.80
U.S. Producer Price Index — Surgical & Medical Instruments
163.40162.90161.70159.60157.80156.90157.10155.20154.40154.10153.60151.00
U.S. Producer Price Index — Surgical Appliances & Supplies
269.30263.80253.80251.40249.60249.50248.70245.40245.10243.70240.10238.50
U.S. Consumer Price Index — Medical Care Commodities
404.90410.40416.80417.00416.50416.00412.60415.90414.50408.30410.10
U.S. Consumer Price Index — Medical Care Services
654.70650.90647.60638.40630.60623.40619.60613.00611.40605.80597.90
U.S. Taxable Hospital Services Revenue (Census QSS)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Total Consolidated Revenue($M)
1,3451,3081,1921,2601,2091,1571,0361,1149941,0049211,035
Cost of Sales($M)
480478442467478468447458400378359378
GAAP Gross Profit($M)
864830750793731689589656594627562657
Research & Development Expense($M)
162153145148158148145140135136142136
Selling, General & Administrative Expense($M)
376359350322331328310327306333319304
GAAP Operating Income($M)
327318255323243213134189152158101217
GAAP Net Income($M)
275249200267284180105152135144146256
Cash & Cash Equivalents($M)
9611,1051,1189181,8361,159905607621939851566
Accounts Receivable, Net($M)
1,1861,2581,0891,2161,1101,3491,1551,0061,002945979974
Inventories, Net($M)
771726694629604571538543586570589560
Property, Plant & Equipment, Net($M)
1,5431,5771,5601,5601,4711,4571,3651,3401,3191,1831,1091,113
Operating Lease Right-of-Use Assets($M)
83.78873.177.45456.459.162.867.571.26871.4
Goodwill($M)
2424.124.224.224.124.123.122.823.823.323.225.2
Total Assets($M)
6,2396,4556,6336,3407,5007,3276,7526,4856,3546,7996,4826,265
Total Liabilities($M)
3,7033,8343,6763,5944,7744,7544,4854,3824,3754,3654,2354,196
Total Stockholders' Equity($M)
2,5352,6212,9572,7462,7262,5732,2672,1031,9792,4342,2472,069
Operating Cash Flow($M)
326269526294660303184301200279209134
Capital Expenditures (Purchases of Property & Equipment)($M)
52.984.776.610280.594.18712511166.156.952.5
Depreciation & Amortization($M)
74.568.267.165.263.6636057.855.352.152.552.5
Share-Based Compensation (Cash Flow Statement)($M)
36.83943.33545.145.334.243.343.444.73936.9

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Operational Drivers: DexCom's continuous glucose monitoring (CGM) model centers on recurring wearable sensor utilization across ~3.5 million global active prescription users (excluding Stelo OTC), commercial and government reimbursement access, and channel mix between wholesale drug/DME distributors (subject to pharmacy benefit manager rebates) and higher-direct-visibility Direct/e-commerce channels.
  • Channel & Product Disaggregation Evolution: Beginning in Q4 2025, DexCom expanded Form 8-K Table C into a 2x2 quarterly revenue matrix across Sales Channel (Distributor vs. Direct) and Geography (United States vs. International), while retiring legacy Table D (Disposable Sensor & Other vs. Reusable Hardware) after integrated wearables pushed sensor and other revenue to 97% of total sales.
  • Consolidated vs. Parent-Only Reporting: DexCom, Inc. reports solely on a consolidated basis under U.S. GAAP without separate parent-company financial statements; key international manufacturing subsidiaries — Dexcom (Malaysia) Sdn. Bhd. in Penang and Dexcom International Limited in Athenry, Ireland — are tracked directly through country-level long-lived asset disclosures.
  • Period Derivations: Quarterly figures not separately printed for Q4 in annual footnotes or Q2–Q4 on cumulative cash flow statements are derived strictly by subtracting prior cumulative periods (Q4 = full year minus nine months; quarter = year-to-date minus prior year-to-date).

Không hiện vì thiếu các kỳ gần đây (12)

  • Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown › Full-Year Revenue Guidance Issued in Quarter — Low Bound › Full-Year Non-GAAP Gross Margin Guidance — Lacks required consecutive latest periods.
  • Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown › Full-Year Revenue Guidance Issued in Quarter — Low Bound › Full-Year Non-GAAP Operating Margin Guidance — Lacks required consecutive latest periods.
  • Organic Growth, Non-GAAP Profitability, Guidance & Segment Expense Breakdown › Full-Year Revenue Guidance Issued in Quarter — Low Bound › Full-Year Adjusted EBITDA Margin Guidance — Lacks required consecutive latest periods.
  • Dexcom CGM Users Connected to Automated Insulin Delivery (AID) Systems Worldwide (1,000,000+) — Disclosed only as a lower-bound milestone ('1,000,000+') at May 2026 Investor Day rather than an exact point series.
  • Health Systems Live or Onboarding with Direct EHR Integration (320+) — Disclosed only as a lower-bound milestone ('320+ health systems') at May 2026 Investor Day.
  • Active Customer Base Annual Growth Rate (>20% in FY2025) — Disclosed only as an inequality bound ('more than 20%') in the 2025 Annual Report Shareholder Letter.
  • International Active CGM Customer Base (~1.1M in FY2025 vs. ~30K in FY2015) — Disclosed for only two non-consecutive milestone years (FY2015 and FY2025) at May 2026 Investor Day; lacks FY2024 for two-year continuity.
  • Dexcom ONE+ Share of EMEA Active Customer Base (~30% at YE 2025) — Single-period year-end 2025 disclosure at May 2026 Investor Day without historical time series.
  • U.S. Covered Lives (~15M in 2026) & Reimbursed Non-Insulin Type 2 Lives via Commercial PBMs (~6M in 2025) — Single-period point disclosures without consecutive prior-year comparatives.
  • Penang Malaysia Facility Waste Diversion Rate (>90%) & On-Site Solar Generation (>4,200,000 kWh) — Disclosed only as lower-bound inequalities ('over 90%', 'over 4,200,000 kWh') in the 2025 Sustainability Report.
  • U.S. State Medicaid Programs Covering CGM (~48 states at year-end 2025) — Disclosed as a point figure in the FY2025 Form 10-K without an equivalent numeric count in the FY2024 Form 10-K.
  • Legally Binding Minimum Payments for Uncommenced Leases ($9.3M at year-end 2025) — Disclosed only for year-end 2025 without consecutive quarterly or prior-year comparatives.

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của DexCom

See a number that looks wrong?